Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Mar 25:2013:694146.
doi: 10.1155/2013/694146. Print 2013.

Biologic complexity in sickle cell disease: implications for developing targeted therapeutics

Affiliations
Review

Biologic complexity in sickle cell disease: implications for developing targeted therapeutics

Beatrice E Gee. ScientificWorldJournal. .

Abstract

Current therapy for sickle cell disease (SCD) is limited to supportive treatment of complications, red blood cell transfusions, hydroxyurea, and stem cell transplantation. Difficulty in the translation of mechanistically based therapies may be the result of a reductionist approach focused on individual pathways, without having demonstrated their relative contribution to SCD complications. Many pathophysiologic processes in SCD are likely to interact simultaneously to contribute to acute vaso-occlusion or chronic vasculopathy. Applying concepts of systems biology and network medicine, models were developed to show relationships between the primary defect of sickle hemoglobin (Hb S) polymerization and the outcomes of acute pain and chronic vasculopathy. Pathophysiologic processes such as inflammation and oxidative stress are downstream by-products of Hb S polymerization, transduced through secondary pathways of hemolysis and vaso-occlusion. Pain, a common clinical trials endpoint, is also complex and may be influenced by factors outside of sickle cell polymerization and vascular occlusion. Future sickle cell research needs to better address the biologic complexity of both sickle cell disease and pain. The relevance of individual pathways to important sickle cell outcomes needs to be demonstrated in vivo before investing in expensive and labor-intensive clinical trials.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Acute pain model. This diagram shows proposed interactions between pathophysiologic mechanisms in sickle cell disease that lead to acute painful episodes. Key to mechanisms: green: balancing feedback loops, red: erythrocytes, orange: hemolysis, light blue: inflammation and oxidant stress, dark blue: ischemia and reperfusion, lavender: vasomotor, brown: coagulation, gray: angiogenesis, and light gray: pain modifiers. See text for details.
Figure 2
Figure 2
Chronic vasculopathy model. This diagram shows proposed interactions between pathophysiologic mechanisms in sickle cell disease that lead to chronic vasculopathy and organ injury. Key to mechanisms: Green arrows: balancing feedback loops, Red: abnormal vascular structure and function, orange: hemolysis, light blue: inflammation and oxidant stress, dark blue: ischemia and reperfusion, lavender: vasomotor, brown: coagulation, and gray: angiogenesis. See text for details.

References

    1. Sickle Cell Disease—Data and Statistics. 2010, http://www.cdc.gov/ncbddd/sicklecell/data.html.
    1. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease—life expectancy and risk factors for early death. The New England Journal of Medicine. 1994;330(23):1639–1644. - PubMed
    1. Sickle Cell Research for Treatment and Cure. National Institutes of Health—National Heart Lung, and Blood Institute; 2002.
    1. Vichinsky E. Emerging “A” therapies in hemoglobinopathies: agonists, antagonists, antioxidants, and arginine. Hematology American Society of Hematology Education Program. 2012;2012:271–275. - PubMed
    1. Hoots WK, Shurin SB. Future directions of sickle cell disease research: the NIH perspective. Pediatric Blood and Cancer. 2012;59(2):353–357. - PMC - PubMed

Publication types

Substances

LinkOut - more resources